Primus Scientific

Profitable. AI-Powered. In a $140B Market That's Accelerating.

Integrated Peptide Platform | Science that works with your body.

Learn More Download Presentation
What We Do
We connect patients to personalized peptide therapies at scale. AI-powered intake, physician matching, and 50-state fulfillment.
We build the commercialization platform for peptide therapies and longevity solutions. GLP-1, hormones, recovery, anti-aging, and next-gen molecules — all on one compliant infrastructure.
We deliver structural efficiency and profitable growth. $1M+ revenue per employee, proprietary Thoryn AI, and a compounding data moat most competitors can’t match.
The Peptide Era

The World Is Entering the Peptide Era

Explore the Peptide Era
$36.5B

Tirzepatide revenue in 2025

$1T

Eli Lilly market cap built on peptide-driven growth

97%+

of eligible patients are still not using GLP-1 therapy (42% of all Americans are the TAM)

Our Solution

AI-Powered. End-to-End. Built to Scale.

Explore the Platform

AI Technology

The intelligence behind the platform.

Already built and operational, now expanding across the entire company.

Telehealth Distribution Platform

AI-powered intake, physician connection, and national-scale delivery.

42% of Americans in the GLP-1 market

Consumer Wellness / D2C Products

Supplements, wellness packs, and holistic health for the mass market.

$150B+ U.S. consumer wellness market

Our Solution

Who We Are

Peptides unlock wellness by closely mimicking the body's natural chemical signals and processes. From weight loss and fat loss to joint regeneration, energy boost, muscle growth, faster recovery, deeper sleep, anti-aging, and skin rejuvenation — the category is exploding.

Primus was architected differently from day one: an end-to-end AI platform that compresses provider workload by 50% while delivering superior clinical accuracy and patient outcomes.

Meet the Team

Exclusive Investor Updates

Join forward-thinking investors and strategic partners for exclusive updates on Primus's growth, regulatory momentum, and next-generation pipeline opportunities — with early access to the full investor presentation and future capital opportunities.

We respect your privacy. Unsubscribe anytime.